ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 001,80
-0,48%
Dow Jones
38 798,99
-0,22%
DAX
18 557,27
-0,48%
Brent Oil
79,395
0,00%
Bitcoin
69 310,73
0,01%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. AstraZeneca PLC (AZN)

  7. AstraZeneca PLC (AZN) Actualités

AZN AstraZeneca PLC

80,02
-0,81 (-1,00%)
08 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
AstraZeneca PLC AZN NASDAQ Certificat de dépôt
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,81 -1,00% 80,02 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
80,31 80,00 80,515 80,02 80,83
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
06/6/202413:00PRNUSI-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical..
04/6/202422:23EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/6/202416:02EDGAR2Form 25-NSE - Notification filed by national security..
04/6/202415:10IHMARKETNEWSEconomic Worries May Lead To Weakness On Wall Street
04/6/202413:00PRNUSAbelZeta announces clinical data showing preliminary..
03/6/202416:29EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/6/202416:23EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/6/202412:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/6/202420:32BWTAGRISSO® (osimertinib) reduced the risk of disease..
02/6/202414:05BWIMFINZI® (durvalumab) is the first and only immunotherapy to..
02/6/202414:00BWENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a..
28/5/202422:30GLOBECellectis Reports Financial Results for First Quarter 2024
28/5/202415:06BWダトポタマブ デルクステカン、..
28/5/202412:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/5/202422:55BWDatopotamab-Deruxtecan zeigt in Phase-III-Studie..
27/5/202419:14BWLe datopotamab deruxtecan a montré une survie globale..
27/5/202413:00BWDatopotamab deruxtecan showed clinically meaningful overall..
23/5/202419:52BWAstraZeneca demonstrates commitment to patients living with..
23/5/202413:00BWAstraZeneca demonstrates commitment to patients living with..
22/5/202413:00BWAstraZeneca furthers ambition to transform outcomes in early..
22/5/202400:44BWアストラゼネカ、2030年までに総収益800億ドルを達成し、2030年以降も持続的な成長を実現するという野心的な目標を設定
21/5/202417:37BWAstraZeneca strebt für 2030 einen Gesamtumsatz von 80..
21/5/202417:36BWAstraZeneca prévoit de réaliser un chiffre d’affaires total..
21/5/202413:18IHMARKETNEWSCalPERS to Oppose Exxon Mobil Directors; Microsoft Unveils..
21/5/202412:08EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/5/202408:00BWAstraZeneca sets ambition to deliver $80 billion Total..
20/5/202412:32EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
19/5/202423:17BWNew data presented at ATS 2024 show the potential of..
13/5/202413:16IHMARKETNEWSArm Sets 2025 Target for AI Chip Development, Amazon and..
06/5/202408:00GLOBECellectis Announces Completion of the Additional Equity..
02/5/202413:00BWCALQUENCE combination regimen demonstrated statistically..
01/5/202413:05BWAstraZeneca unveils latest research across key respiratory..
29/4/202413:00BWENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in..
25/4/202414:00PRNUSAbelZeta Announces Abstract for C-CAR031 Accepted for..
25/4/202413:53IHMARKETNEWSU.S. Futures Drop in Pre-Market Trading as Tech Stocks..
25/4/202413:52IHMARKETNEWSSouthwest Shares Tumble 9.6% Post $231 Million 1Q Loss,..
25/4/202408:00BWQ1 2024 results
16/4/202413:00BWIMFINZI® (durvalumab) plus chemotherapy doubled overall..
12/4/202413:05IHMARKETNEWSParamount Global Board Shrinks, Morgan Stanley Faces..
11/4/202413:24IHMARKETNEWSCostco Increases Dividend by 14%, Meta Introduces ‘Artemis’..
11/4/202413:00BWFASENRA approved for treatment of children aged 6 to 11 with..
06/4/202405:10BWENHERTU® Approved in the U.S. as First Tumor Agnostic HER2..
06/4/202403:43BWENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the..
05/4/202413:00BWIMFINZI® (durvalumab) significantly improved overall..
02/4/202413:00BWDatopotamab deruxtecan Biologics License Application..
02/4/202408:00BWDatopotamab Deruxtecan Biologics License Application..
01/4/202413:00BWVOYDEYA™ approved in the US as add-on therapy to ravulizumab..
27/3/202411:54IHMARKETNEWSGameStop Shares Tumble 20% in Pre-Market Trading Amid..
26/3/202412:20IHMARKETNEWSSuper Micro Computer and Seagate Shares Surge on Analyst..
25/3/202412:00BWULTOMIRIS® (ravulizumab-cwvz) approved in the US for the..

Dernières Valeurs Consultées

NASDAQ
AZN
AstraZeneca
COIN
FNXXETH
FinNexus
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés